About 8 results found for searched term "57-41-0" (0.063 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M5295 | MI-538 | Epigenetic Reader Domain |
| Mi-538 is an inhibitor of the interaction between MENin and MLL fusion protein with an IC50 value of 21 nM. | ||
| M5875 | Phenytoin | Sodium Channel |
| Diphenylhydantoin; 5,5-Diphenylhydantoin | ||
| Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na+ channels (VGSCs) blocker. Phenytoin reduces breast tumour growth and metastasis in mice, and it also has antiepileptic activity. | ||
| M9151 | MI-503 | Histone Methyltransferase |
| MI-503 is a potent and selective Menin-MLL inhibitor with IC50 of 14.7 nM. | ||
| M24559 | Vorsetuzumab mafodotin | Drug-Linker Conjugates for ADC |
| Anti-Human CD70 Recombinant Antibody; SGN-75 | ||
| Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity. | ||
| M40391 | Taxuspine B | Others |
| Taxuspine B is a natural product, that can be isolated from Japanese yew Taxus. Taxuspine B exhibits appreciable taxol-like activity to reduce CaCl2-induced depolymerixation of microtubules among the taxoids. | ||
| M41768 | Moprolol | Adrenergic Receptor |
| Moprolol ((±)-Moprolol) is an beta-adrenergic receptor blocker, which can be used for research in essential hypertension. | ||
| M49801 | 5A2-SC8 | Liposome |
| 5A2-SC8 is a degradable lipid-like compound (ester-based dendrimer) that can be used for small RNA delivery. | ||
| M53536 | CEF19, Epstein-Barr Virus latent NA-3A (458-466) | Anti-infection |
| CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
